
Multiple Myeloma
Latest News
Latest Videos

CME Content
More News
















A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.

The addition of panobinostat to bortezomib and dexamethasone improved progression-free survival by 7.8 months in a subgroup of 147 patients with multiple myeloma who had received at least 2 prior treatments, including bortezomib and an immunomodulatory agent.






Saad Z. Usmani, MD, director, Clinical Research Hematologic Malignancies, director, Plasma Cell Disorders, Levine Cancer Institute/Carolinas Healthcare System, discusses daratumumab for patients with relapsed/refractory multiple myeloma.

Sagar Lonial, MD, discusses the future of monoclonal antibodies in multiple myeloma.















































